carboplatin + cisplatin + docetaxel + gemcitabine + paclitaxel + pemetrexed

This is a combination chemotherapy regimen consisting of six cytotoxic agents commonly used in the treatment of various solid tumors, particularly non-small cell lung cancer (NSCLC). The drugs included are:\n- Carboplatin and cisplatin, both platinum-based compounds that cause DNA crosslinking and inhibit DNA synthesis.\n- Docetaxel and paclitaxel, which are taxane derivatives that stabilize microtubules and prevent cell division.\n- Gemcitabine, a nucleoside analog that inhibits DNA synthesis by incorporation into DNA strands.\n- Pemetrexed, an antifolate agent that disrupts folate-dependent metabolic processes essential for cell replication.\n\nEach drug has demonstrated efficacy as part of doublet or triplet regimens in NSCLC and other cancers. However, the simultaneous use of all six agents together is not standard clinical practice due to significant overlapping toxicities. Combinations involving subsets of these drugs (e.g., carboplatin/gemcitabine[4], cisplatin/gemcitabine[2], docetaxel/pemetrexed[1], pemetrexed/paclitaxel[1]) have been studied for advanced NSCLC with varying degrees of efficacy and tolerability. The rationale behind combining multiple mechanisms includes maximizing tumor cytotoxicity through different pathways—DNA damage (platinum agents), mitotic arrest (taxanes), antimetabolite effects (gemcitabine/pemetrexed)—but at the cost of increased toxicity.